secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001437749-25-036507
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.02, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros closes zaltenibart sale to Novo Nordisk for $240M upfront; repays debt, launches $100M buyback
--------------------------------------------------------------------------------

- Closed sale of zaltenibart to Novo Nordisk for $240M upfront; eligible for up to $2.1B in milestones plus tiered royalties on net sales.
- Used $72.6M of proceeds to repay $67.1M term loan, prepayment premium, interest; Credit Agreement terminated.
- Board authorized up to $100M share repurchase program for common stock with indefinite term.
- Remaining cash expected to fund >12 months of operations, including narsoplimab launch for TA-TMA.
- Pro forma financials show net income of $124.4M for FY2024 and net loss of $69.9M for 9M2025 after asset sale adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925036507/0001437749-25-036507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925036507/omer20251024_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-036507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer